Search

everythinglearnresearchcommunity

for

Search:↓

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.

A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.

Belimumab may cause hair loss in lupus patients.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

A patient's grey hair regained color during treatment with adalimumab.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

Tofacitinib helped a woman regrow hair with no major side effects.

The combination therapy was effective and well-tolerated, especially in young patients.

Ocrelizumab may cause total body hair loss in some patients.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.